SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/17 – ‘EX-31.2’

On:  Friday, 12/29/17, at 3:46pm ET   ·   For:  9/30/17   ·   Accession #:  1615774-17-7691   ·   File #:  1-35527

Previous ‘10-K’:  ‘10-K’ on 12/22/16 for 9/30/16   ·   Next:  ‘10-K’ on 12/11/18 for 9/30/18   ·   Latest:  ‘10-K’ on 3/31/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/29/17  Emmaus Life Sciences, Inc.        10-K        9/30/17   71:8.8M                                   S2 Filings LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    987K 
 2: EX-4.3      Instrument Defining the Rights of Security Holders  HTML     17K 
 3: EX-21.1     Subsidiaries List                                   HTML     18K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     20K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
16: R1          Document and Entity Information                     HTML     49K 
17: R2          Consolidated Balance Sheets                         HTML    106K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
19: R4          Consolidated Statements of Operations               HTML     68K 
20: R5          Consolidated Statements of Changes in               HTML     83K 
                Stockholders' Equity (Deficit)                                   
21: R6          Consolidated Statements of Cash Flows               HTML    112K 
22: R7          Nature of Operations                                HTML     42K 
23: R8          Summary of Significant Accounting Policies          HTML     78K 
24: R9          Convertible Debt and Equity Financings              HTML    151K 
25: R10         Derivative Liabilities                              HTML     52K 
26: R11         Stockholders' Equity                                HTML    239K 
27: R12         Income Taxes                                        HTML     51K 
28: R13         Related Party Transactions                          HTML     63K 
29: R14         Loss Per Share                                      HTML     35K 
30: R15         Commitments and Contingent Liabilities              HTML     39K 
31: R16         Significant Customers                               HTML     23K 
32: R17         Subsequent Events                                   HTML     24K 
33: R18         Summary of Significant Accounting Policies          HTML    138K 
                (Policies)                                                       
34: R19         Summary of Significant Accounting Policies          HTML     25K 
                (Tables)                                                         
35: R20         Convertible Debt and Equity Financings (Tables)     HTML    121K 
36: R21         Derivative Liabilities (Tables)                     HTML     40K 
37: R22         Stockholders' Equity (Tables)                       HTML    184K 
38: R23         Income Taxes (Tables)                               HTML     48K 
39: R24         Related Party Transactions (Tables)                 HTML     40K 
40: R25         Loss Per Share (Tables)                             HTML     34K 
41: R26         Commitments and Contingent Liabilities (Tables)     HTML     29K 
42: R27         Nature of Operations (Details Narrative)            HTML     84K 
43: R28         Summary of Significant Accounting Policies          HTML     26K 
                (Details)                                                        
44: R29         Summary of Significant Accounting Policies          HTML     65K 
                (Details Narrative)                                              
45: R30         Convertible Debt and Equity Financings (Details)    HTML    123K 
46: R31         Convertible Debt and Equity Financings (Details     HTML    185K 
                Narrative)                                                       
47: R32         Derivative Liabilities (Details)                    HTML     56K 
48: R33         Derivative Liabilities (Details Narrative)          HTML     92K 
49: R34         Stockholders' Equity (Details)                      HTML     32K 
50: R35         Stockholders' Equity (Details 1)                    HTML     26K 
51: R36         Stockholders' Equity (Details 2)                    HTML     53K 
52: R37         Stockholders' Equity (Details 3)                    HTML    128K 
53: R38         Stockholders' Equity (Details 4)                    HTML     50K 
54: R39         Stockholders' Equity (Details 5)                    HTML     32K 
55: R40         Stockholders' Equity (Details 6)                    HTML     42K 
56: R41         Stockholders' Equity (Details 7)                    HTML     57K 
57: R42         Stockholders' Equity (Details Narrative)            HTML    611K 
58: R43         Stockholders' Equity (Details Narrative 1)          HTML     48K 
59: R44         Income Taxes (Details)                              HTML     40K 
60: R45         Income Taxes (Details 1)                            HTML     39K 
61: R46         Income Taxes (Details Narrative)                    HTML     25K 
62: R47         Related Party Transactions (Details)                HTML     53K 
63: R48         Related Party Transactions (Details Narrative)      HTML    147K 
64: R49         Loss Per Share (Details)                            HTML     41K 
65: R50         Commitments and Contingent Liabilities (Details)    HTML     42K 
66: R51         Commitments and Contingent Liabilities (Details     HTML     83K 
                Narrative)                                                       
67: R52         Significant Customers (Details Narrative)           HTML     29K 
68: R53         Subsequent Events (Details Narrative)               HTML     36K 
70: XML         IDEA XML File -- Filing Summary                      XML    119K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
10: EX-101.INS  XBRL Instance -- myan-20170930                       XML   2.60M 
12: EX-101.CAL  XBRL Calculations -- myan-20170930_cal               XML    151K 
13: EX-101.DEF  XBRL Definitions -- myan-20170930_def                XML    843K 
14: EX-101.LAB  XBRL Labels -- myan-20170930_lab                     XML   1.24M 
15: EX-101.PRE  XBRL Presentations -- myan-20170930_pre              XML   1.05M 
11: EX-101.SCH  XBRL Schema -- myan-20170930                         XSD    194K 
71: ZIP         XBRL Zipped Folder -- 0001615774-17-007691-xbrl      Zip    195K 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 31.2

 

Certification of Principal Financial Officer 

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

 

I, Donald D’Ambrosio, certify that:

 

  1. I have reviewed this Form 10-K of MYnd Analytics, Inc. for the fiscal year ended September 30, 2017;
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

December 29, 2017 /s/ Donald D’Ambrosio
  Name: Donald D’Ambrosio
  Title: Chief Financial Officer (Principal Financial Officer)

 

 C: 

 


Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:12/29/17None on these Dates
For Period end:9/30/17
 List all Filings 
Top
Filing Submission 0001615774-17-007691   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 18, 11:54:38.1pm ET